Re: Racial and Sociodemographic Disparities in Hepatitis C Treatment at an Urban Academic Medical Center, 2018-2023 - Takeaways - MDSpire

Re: Racial and Sociodemographic Disparities in Hepatitis C Treatment at an Urban Academic Medical Center, 2018-2023

  • By

  • Heather Lopez

  • Jeffrey D Klausner

  • Chrysovalantis Stafylis

  • December 3, 2025

  • 0 min

Share

  • 1

    Only 26.5% of hepatitis C patients were treated at an urban academic center, with treatment rates varying significantly by insurance type.

  • 2

    In Los Angeles County, 69% of hepatitis C patients remain untreated, with higher rates among those with no or public insurance.

  • 3

    California's Medicaid program removed prior authorization restrictions for hepatitis C treatment in 2024, yet disparities persist.

  • 4

    Prior authorization barriers delay hepatitis C treatment initiation, contributing to high rates of untreated cases and increased healthcare costs.

  • 5

    Eliminating prior authorization across all insurance types is essential for equitable hepatitis C virus elimination in the United States.

Original Source(s)

Re: Racial and Sociodemographic Disparities in Hepatitis C Treatment at an Urban Academic Medical Center, 2018-2023

  • by Heather Lopez, Jeffrey D Klausner, Chrysovalantis Stafylis

  • December 3, 2025

Related Content

Accessing Syringe Services Programs in the US: Analyzing Travel Time, Distance, and Associated Costs

The Loan Cap That Could Shrink the Doctor Pipeline

New federal limits on medical school borrowing may quietly reshape who becomes a physician—and where they practice.

Regional Mortality From Chronic Liver Diseases in African Countries Attributable to Hepatitis B Virus and Hepatitis C Virus Infections From 1990 to 2021 and Projections to 2030